Idetrexed plus olaparib for high-grade serous ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, multi-site dose-escalation and dose-expansion trial gives increasing doses of the folate-receptor-targeted thymidylate synthase inhibitor idetrexed together with the PARP inhibitor olaparib to determine safety, tolerability, and a recommended dose. Early cohorts follow a standard dose-escalation schema to define the maximum tolerated dose, followed by an expansion cohort enriched for tumors with medium-to-high alpha-folate receptor expression. The combination aims to increase DNA damage in cancer cells via thymidylate synthase inhibition while blocking DNA repair with a PARP inhibitor to enhance cancer cell death. Trial sites are established cancer centers in the United Kingdom and patients are followed for safety, pharmacokinetics, and preliminary anti-tumor activity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically or cytologically proven high grade serous ovarian cancer refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient.
* Measurable (as defined by RECIST v1.1) or evaluable (based on tumour markers) disease.
* Life expectancy of at least 12 weeks.
* World Health Organisation (WHO) performance status of 0-1 (Appendix 1 of Protocol).
* Haematological and biochemical indices within the ranges shown in Protocol section 4.1.1). These measurements must be performed within one week (Day -7 to Day 1) prior to the patient's first dose of IMP.

Normal (no clinically significant abnormalities) 12-lead ECG, QTcF interval \<470 ms

* Pulmonary function test FVC of \>70%, DLCOc (DLCO corrected for Hb) of \>60%.
* 18 years or over.
* Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up.
* For dose expansion patients only, they must have medium to high α-folate receptor expression according to the Ventana FOLR1-2.1 IHC assay.

Exclusion Criteria:

* Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C) and 4 weeks for investigational medicinal products) before treatment.
* Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the DDU should not exclude the patient.
* Patients with new brain metastases. Patients with treated (surgically excised or irradiated) and stable brain metastases are eligible as long as the treatment was at least 4 weeks prior to initiation of study drug and brain MRI within 2 weeks of initiation of study drug is negative for new metastases.
* Patients with pulmonary metastases.
* History of thoracic radiation or other history likely to create pre-existing lung disease
* Presence of significant clinical ascites and/or pleural effusions.
* Female patients of child-bearing potential (or are already pregnant or lactating). However, those patients who have a negative serum or urine pregnancy test before enrolment and agree to use two forms of contraception (one effective form plus a barrier method) \[oral, injected or implanted hormonal contraception and condom; intra-uterine device and condom; diaphragm with spermicidal gel and condom\] or agree to sexual abstinence (see Protocol Section 16.5 - Appendix 5), effective from signing the consent form, throughout the trial and for six months afterwards are considered eligible.
* Major thoracic or abdominal surgery from which the patient has not yet recovered.
* Patients with sub-acute bowel obstruction.
* Organ transplant patients.
* At high medical risk because of non-malignant systemic disease including active uncontrolled infection.
* Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
* Patients with history of QT prolongation, clinically significant VT, VF, heart block, MI within 1 year, CHF NYHA Class III or IV, unstable angina, angina within 6 months, or other evidence of clinically significant coronary artery disease/
* Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase I/Ib study of Idetrexed and Olaparib. Participation in an observational trial would be acceptable.
* Inability to tolerate Olaparib.
* Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
* Confirmed, current COVID-19 infection.

Where it's running

• Royal Marsden Hospital - Drug Development Unit
  Sutton, London, United Kingdom Recruiting
• Addenbrooke's Hospital
  Cambridge, Cambridgeshire, United Kingdom Not yet recruiting
• Velindre Cancer Centre
  Cardiff, Wales, United Kingdom Not yet recruiting

Study contacts

• Principal investigator: Professor Udai Banerji — Institute of Cancer Research, United Kingdom
• Study coordinator: Alexander Cowley, Ph.D.
• Email: idol@icr.ac.uk
• Phone: +44 20 3437 6927

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FRα expression in high-grade serous ovarian cancer (FRα positive)

  A retrospective study in Greece will test how often Folate Receptor Alpha is present in tumor samples from adults diagnosed with high-grade serous ovarian cancer.

  Recruiting Hellenic Cooperative Oncology Group · Athens · NCT07889843

• Routine shallow-coverage Whole Genome Sequencing of Cervical Smears to See if Ovarian Cancer is Found Earlier

  Researchers test whether analyzing DNA from cervical smears with shallow whole-genome sequencing can help detect high-grade serous ovarian cancer early in patients undergoing treatment for this cancer.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07821879

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Investigating the Role of RPL8 Protein in Ovarian Cancer

  This study is trying to see if the RPL8 protein in ovarian cancer tumors can help doctors understand the disease better and make more informed treatment choices for patients.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT06777082

• Exploring Tumor Biology in Ovarian Cancer with Advanced Imaging Techniques

  This study is testing new imaging techniques to better understand ovarian cancer tumors and improve personalized treatment for patients.

  Recruiting Institut du Cancer de Montpellier - Val d'Aurelle · Montpellier · NCT06084195

• Testing Rinatabart Sesutecan for advanced solid tumors

  This study is testing a new drug called Rinatabart Sesutecan to see if it can safely help people with advanced solid tumors, like certain types of ovarian and endometrial cancers.

  Recruiting at 67 sites Phase 1/2 Genmab · Phoenix, Arizona and 66 other locations · NCT05579366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.